BACE1 Physiological Functions May Limit Its Use as Therapeutic Target for Alzheimer's Disease

Trends in Neurosciences

Volumn 39, Issue 3, 2016, Pages 158-169

  Barão, Soraia ^a,b   Moechars, Diederik ^c   Lichtenthaler, Stefan F ^d,e   De Strooper, Bart ^a,b,f  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^d Technische Universität München Munich Cluster for Systems Neurology   (Germany)

^e TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Alzheimer's disease; APP; BACE1; C terminal fragments; Therapeutic target

Indexed keywords

BETA SECRETASE 1; BETA SECRETASE 2; ASPARTIC PROTEINASE; BACE1 PROTEIN, HUMAN; BACE1 PROTEIN, MOUSE; PROTEINASE INHIBITOR; SECRETASE;

ALZHEIMER DISEASE; BRAIN FUNCTION; ENDOSOME; HUMAN; MYELINATION; NERVE FIBER; NEUROPHYSIOLOGY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; ANIMAL; ANTAGONISTS AND INHIBITORS; DISEASE MODEL; ENZYMOLOGY; GENETICS; METABOLISM; MOUSE;

ALZHEIMER DISEASE; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ASPARTIC ACID ENDOPEPTIDASES; DISEASE MODELS, ANIMAL; HUMANS; MICE; PROTEASE INHIBITORS;

EID: 84975770550     PISSN: 01662236     EISSN: 1878108X     Source Type: Journal    
DOI: 10.1016/j.tins.2016.01.003     Document Type: Review

References (88)

1. De Strooper B. Proteases and proteolysis in Alzheimer disease: a multifactorial view on the disease process. Physiol. Rev. 2010, 90:465-494.
2. Luo Y., et al. Mice deficient in BACE1, the Alzheimer's β-secretase, have normal phenotype and abolished β-amyloid generation. Nat. Neurosci. 2001, 4:231-232.
3. Jonsson T., et al. A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature 2012, 488:96-99.
4. Di Fede G., et al. A recessive mutation in the APP gene with dominant-negative effect on amyloidogenesis. Science 2009, 323:1473-1477.
5. Benilova I., et al. The Alzheimer disease protective mutation A2T modulates kinetic and thermodynamic properties of amyloid-β (Aβ) aggregation. J. Biol. Chem. 2014, 289:30977-30989.
6. Vassar R., et al. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 1999, 286:735-741.
7. Zhao J., et al. Beta-site amyloid precursor protein cleaving enzyme 1 levels become elevated in neurons around amyloid plaques: implications for Alzheimer's disease pathogenesis. J. Neurosci. 2007, 27:3639-3649.
8. Kandalepas P.C., et al. The Alzheimer's β-secretase BACE1 localizes to normal presynaptic terminals and to dystrophic presynaptic terminals surrounding amyloid plaques. Acta Neuropathol. 2013, 126:329-352.
9. Yang L.B., et al. Elevated β-secretase expression and enzymatic activity detected in sporadic Alzheimer disease. Nat. Med. 2003, 9:3-4.
10. Vassar R., et al. Function, therapeutic potential and cell biology of BACE proteases: current status and future prospects. J. Neurochem. 2014, 130:4-28.
11. Kizuka Y., et al. An aberrant sugar modification of BACE1 blocks its lysosomal targeting in Alzheimer's disease. EMBO Mol. Med. 2015, 7:175-189.
12. Akasaka-Manya K., et al. Protective effect of N-glycan bisecting GlcNAc residues on β-amyloid production in Alzheimer's disease. Glycobiology 2010, 20:99-106.
13. Bhattacharyya R., et al. Truncated, inactive N-acetylglucosaminyltransferase III (GlcNAc-TIII) induces neurological and other traits absent in mice that lack GlcNAc-TIII. J. Biol. Chem. 2002, 277:26300-26309.
14. Rajendran L., Annaert W. Membrane trafficking pathways in Alzheimer's disease. Traffic 2012, 13:759-770.
15. Cataldo A.M., et al. Endocytic pathway abnormalities precede amyloid β deposition in sporadic Alzheimer's disease and Down syndrome. Am. J. Pathol. 2000, 157:277-286.
16. Ginsberg S.D., et al. Microarray analysis of hippocampal CA1 neurons implicates early endosomal dysfunction during Alzheimer's disease progression. Biol. Psychiatry 2010, 68:885-893.
17. Morel E., et al. Phosphatidylinositol-3-phosphate regulates sorting and processing of amyloid precursor protein through the endosomal system. Nat. Commun. 2013, 4:2250.
18. Jiang Y., et al. Alzheimer's-related endosome dysfunction in Down syndrome is Aβ-independent but requires APP and is reversed by BACE-1 inhibition. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:1630-1635.
19. Kim S., et al. Evidence that the rab5 effector APPL1 mediates APP-βCTF-induced dysfunction of endosomes in Down syndrome and Alzheimer's disease. Mol. Psychiatry 2015, Published online July 21, 2015. 10.1038/mp.2015.97.
20. Harrison S.M., et al. BACE1 (β-secretase) transgenic and knockout mice: identification of neurochemical deficits and behavioral changes. Mol. Cell. Neurosci. 2003, 24:646-655.
21. Dominguez D., et al. Phenotypic and biochemical analyses of BACE1- and BACE2-deficient mice. J. Biol. Chem. 2005, 280:30797-30806.
22. Hu X., et al. BACE1 deficiency causes altered neuronal activity and neurodegeneration. J. Neurosci. 2010, 30:8819-8829.
23. Willem M., et al. Control of peripheral nerve myelination by the β-secretase BACE1. Science 2006, 314:664-666.
24. Hu X., et al. Bace1 modulates myelination in the central and peripheral nervous system. Nat. Neurosci. 2006, 9:1520-1525.
25. Hu X., et al. Genetic deletion of BACE1 in mice affects remyelination of sciatic nerves. FASEB J. 2008, 22:2970-2980.
26. Laird F.M., et al. BACE1, a major determinant of selective vulnerability of the brain to amyloid-β amyloidogenesis, is essential for cognitive, emotional, and synaptic functions. J. Neurosci. 2005, 25:11693-11709.
27. Kobayashi D., et al. BACE1 gene deletion: impact on behavioral function in a model of Alzheimer's disease. Neurobiol. Aging 2008, 29:861-873.
28. Wang H., et al. BACE1 knock-outs display deficits in activity-dependent potentiation of synaptic transmission at mossy fiber to CA3 synapses in the hippocampus. J. Neurosci. 2008, 28:8677-8681.
29. Filser S., et al. Pharmacological inhibition of BACE1 impairs synaptic plasticity and cognitive functions. Biol. Psychiatry 2014, 77:729-739.
30. Savonenko A.V., et al. Alteration of BACE1-dependent NRG1/ErbB4 signaling and schizophrenia-like phenotypes in BACE1-null mice. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:5585-5590.
31. Hu X., et al. BACE1 regulates hippocampal astrogenesis via the Jagged1-Notch pathway. Cell Rep. 2013, 4:40-49.
32. Rajapaksha T.W., et al. The Alzheimer's β-secretase enzyme BACE1 is required for accurate axon guidance of olfactory sensory neurons and normal glomerulus formation in the olfactory bulb. Mol. Neurodegener. 2011, 6:88.
33. Cao L., et al. The precision of axon targeting of mouse olfactory sensory neurons requires the BACE1 protease. Sci. Rep. 2012, 2:1-8.
34. Hitt B., et al. β-Site amyloid precursor protein (APP)-cleaving enzyme 1 (BACE1)-deficient mice exhibit a close homolog of L1 (CHL1) loss-of-function phenotype involving axon guidance defects. J. Biol. Chem. 2012, 287:38408-38425.
35. Barão S., et al. Antagonistic effects of BACE1 and APH1B-γ-secretase control axonal guidance by regulating growth cone collapse. Cell Rep. 2015, 12:1367-1376.
36. Cheret C., et al. Bace1 and Neuregulin-1 cooperate to control formation and maintenance of muscle spindles. EMBO J. 2013, 32:2015-2028.
37. Cai J., et al. β-Secretase (BACE1) inhibition causes retinal pathology by vascular dysregulation and accumulation of age pigment. EMBO Mol. Med. 2012, 4:980-991.
38. -/- mice exhibit seizure activity that does not correlate with sodium channel level or axonal localization. Mol. Neurodegener. 2010, 5:31.
39. Kitazume S., et al. In vivo cleavage of α2,6-sialyltransferase by Alzheimer β-secretase. J. Biol. Chem. 2005, 280:8589-8595.
40. Von Einem B., et al. The role of low-density receptor-related protein 1 (LRP1) as a competitive substrate of the amyloid precursor protein (APP) for BACE1. Exp. Neurol. 2010, 225:85-93.
41. Hemming M.L., et al. Identification of β-secretase (BACE1) substrates using quantitative proteomics. PLoS ONE 2009, 4:e8477.
42. Wong H.K., et al. β-Subunits of voltage-gated sodium channels are novel substrates of β-site amyloid precursor protein-cleaving enzyme (BACE1) and γ-secretase. J. Biol. Chem. 2005, 280:23009-23017.
43. Kim D.Y., et al. BACE1 regulates voltage-gated sodium channels and neuronal activity. Nat. Cell Biol. 2007, 9:755-764.
44. Kuhn P.H., et al. Secretome protein enrichment identifies physiological BACE1 protease substrates in neurons. EMBO J. 2012, 31:3157-3168.
45. Dislich B., et al. Label-free quantitative proteomics of mouse cerebrospinal fluid detects β-site APP cleaving enzyme (BACE1) protease substrates in vivo. Mol. Cell. Proteomics 2015, 14:2550-2563.
46. Zhou L., et al. The neural cell adhesion molecules L1 and CHL1 are cleaved by BACE1 protease in vivo. J. Biol. Chem. 2012, 287:25927-25940.
47. Fazzari P., et al. Cell autonomous regulation of hippocampal circuitry via Aph1b-γ-secretase/Neuregulin 1 signalling. Elife 2014, Published online June 2, 2014. 10.7554/eLife.02196.
48. Montag-Sallaz M., et al. Misguided axonal projections, neural cell adhesion molecule 180 mRNA upregulation, and altered behavior in mice deficient for the close homolog of L1. Mol. Cell. Biol. 2002, 22:7967-7981.
49. Castellani V., et al. Analysis of the L1-deficient mouse phenotype reveals cross-talk between Sema3A and L1 signaling pathways in axonal guidance. Neuron 2000, 27:237-249.
50. Bagnard D., et al. Axonal surface molecules act in combination with semaphorin 3a during the establishment of corticothalamic projections. Cereb. Cortex 2001, 11:278-285.
51. Sahay A., et al. Secreted semaphorins modulate synaptic transmission in the adult hippocampus. J. Neurosci. 2005, 25:3613-3620.
52. Wright A.G., et al. Close homolog of L1 and neuropilin 1 mediate guidance of thalamocortical axons at the ventral telencephalon. J. Neurosci. 2007, 27:13667-13679.
53. Bagri A., et al. Stereotyped pruning of long hippocampal axon branches triggered by retraction inducers of the semaphorin family. Cell 2003, 113:285-299.
54. Urban N.N., et al. Revisiting the role of the hippocampal mossy fiber synapse. Hippocampus 2001, 11:408-417.
55. Kerjan G., et al. Mice lacking doublecortin and doublecortin-like kinase 2 display altered hippocampal neuronal maturation and spontaneous seizures. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:6766-6771.
56. Bai G., et al. Presenilin-dependent receptor processing is required for axon guidance. Cell 2011, 144:106-118.
57. Romi E., et al. ADAM metalloproteases promote a developmental switch in responsiveness to the axonal repellant Sema3A. Nat. Commun. 2014, 5:4058.
58. Hessler S., et al. β-Secretase BACE1 regulates hippocampal and reconstituted M-currents in a β-subunit-like fashion. J. Neurosci. 2015, 35:3298-3311.
59. De Strooper B. Lessons from a failed γ-secretase Alzheimer trial. Cell 2014, 159:721-726.
60. Avci D., Lemberg M.K. Clipping or extracting: two ways to membrane protein degradation. Trends Cell Biol. 2015, 25:611-622.
61. Bennett B.D., et al. Expression analysis of BACE2 in brain and peripheral tissues. J. Biol. Chem. 2000, 275:20647-20651.
62. Farzan M., et al. BACE2, a β-secretase homolog, cleaves at the β site and within the amyloid-β region of the amyloid-β precursor protein. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:9712-9717.
63. Cahoy J.D., et al. A transcriptome database for astrocytes, neurons, and oligodendrocytes: a new resource for understanding brain development and function. J. Neurosci. 2008, 28:264-278.
64. Esterházy D., et al. Bace2 is a β cell-enriched protease that regulates pancreatic β cell function and mass. Cell Metab. 2011, 14:365-377.
65. Rochin L., et al. BACE2 processes PMEL to form the melanosome amyloid matrix in pigment cells. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:10658-10663.
66. Stutzer I., et al. Systematic proteomic analysis identifies β-site amyloid precursor protein cleaving enzyme 2 and 1 (BACE2 and BACE1) substrates in pancreatic β-cells. J. Biol. Chem. 2013, 288:10536-10547.
67. May P.C., et al. Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitor. J. Neurosci. 2011, 31:16507-16516.
68. Saftig P., et al. Mice deficient for the lysosomal proteinase cathepsin D exhibit progressive atrophy of the intestinal mucosa and profound destruction of lymphoid cells. EMBO J. 1995, 14:3599-3608.
69. Shacka J.J., et al. Cathepsin D deficiency induces persistent neurodegeneration in the absence of Bax-dependent apoptosis. J. Neurosci. 2007, 27:2081-2090.
70. May P.C., et al. The potent BACE1 inhibitor LY2886721 elicits robust central Aβ pharmacodynamic responses in mice, dogs, and humans. J. Neurosci. 2015, 35:1199-1210.
71. Forman M., et al. The novel BACE inhibitor MK-8931 dramatically lowers cerebrospinal fluid Aβ peptides in healthy subjects following single- and multiple-dose administration. Alzheimers Demen. 2012, 8:P704.
72. Forman M., et al. The novel BACE inhibitor MK-8931 dramatically lowers CSF β-amyloid in patients with mild-to-moderate Alzheimer's disease. Alzheimers Demen. 2013, 9:P139.
73. Jack C.R., et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 2010, 9:119-128.
74. Zhong Z., et al. Levels of β-secretase (BACE1) in cerebrospinal fluid as a predictor of risk in mild cognitive impairment. Arch. Gen. Psychiatry 2007, 64:718-726.
75. Verheijen J.H., et al. Detection of a soluble form of BACE-1 in human cerebrospinal fluid by a sensitive activity assay. Clin. Chem. 2006, 52:1168-1174.
76. Ewers M., et al. Increased CSF-BACE 1 activity is associated with ApoE-e4 genotype in subjects with mild cognitive impairment and Alzheimer's disease. Brain 2008, 131:1252-1258.
77. Zetterberg H., et al. Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease. Arch. Neurol. 2008, 65:1102-1107.
78. Mulder S.D., et al. BACE1 activity in cerebrospinal fluid and its relation to markers of AD pathology. J. Alzheimers Dis. 2010, 20:253-260.
79. Wu G., et al. Decrease in age-adjusted cerebrospinal fluid β-secretase activity in Alzheimer's subjects. Clin. Biochem. 2008, 41:986-996.
80. Barao S., et al. BACE1 levels correlate with phospho-tau levels in human cerebrospinal fluid. Curr. Alzheimer Res. 2013, 10:671-678.
81. Blennow K., et al. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease?. Mol. Chem. Neuropathol. 1995, 26:231-245.
82. Gonzales A., et al. Development of a specific ELISA to measure BACE1 levels in human tissues. J. Neurosci. Methods 2011, 202:70-76.
83. Willem M., et al. η-Secretase processing of APP inhibits neuronal activity in the hippocampus. Nature 2015, 526:443-447.
84. Zhang Z., et al. δ-Secretase cleaves amyloid precursor protein and regulates the pathogenesis in Alzheimer's disease. Nat. Commun. 2015, 6:8762.
85. Reiner Z. Statins in the primary prevention of cardiovascular disease. Nat. Rev. Cardiol. 2013, 10:453-464.
86. McConlogue L., et al. Partial reduction of BACE1 has dramatic effects on Alzheimer plaque and synaptic pathology in APP transgenic mice. J. Biol. Chem. 2007, 282:26326-26334.
87. Ohno M., et al. BACE1 gene deletion prevents neuron loss and memory deficits in 5XFAD APP/PS1 transgenic mice. Neurobiol. Dis. 2007, 26:134-145.
88. De Strooper B., Voet T. Alzheimer's disease: a protective mutation. Nature 2012, 488:38-39.